Roivant Sciences (ROIV) | Stock Overview & Key Data
Roivant Sciences Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $32.79 on May 20, 2026
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Roivant Sciences
ROIV
|
20.14B Large-cap | 5.41% | 2.53% | 6.19% | 37.12% | 36.94% | 165.37% | 211.30% | 203.43% | 202.82% | 202.82% | 202.82% |
|
Vertex
VRTX
|
109.45B Large-cap | 1.69% | 3.09% | -3.36% | -1.15% | -0.37% | -2.31% | 27.89% | 136.85% | 413.01% | 888.51% | 1,245.83% |
|
Regeneron
REGN
|
80.98B Large-cap | 0.60% | -11.93% | -18.75% | -18.29% | -20.78% | 15.66% | -21.83% | 13.80% | 72.82% | 1,033.17% | 4,804.97% |
|
Alnylam
ALNY
|
41.87B Large-cap | -1.49% | 0.29% | -9.76% | -26.49% | -28.08% | -8.16% | 40.32% | 59.90% | 405.36% | 3,032.34% | 1,907.45% |
|
Insmed
INSM
|
31.05B Large-cap | 3.49% | -10.70% | -32.60% | -50.51% | -44.98% | -0.89% | 389.25% | 236.25% | 934.36% | 717.46% | 614.23% |
|
Revolution Medicines
RVMD
|
28.61B Large-cap | 7.79% | 9.89% | 61.68% | 102.61% | 102.56% | 279.08% | 524.98% | 353.09% | 443.52% | 443.52% | 443.52% |
Ownership & Short Interest
Calculate Your Roivant Sciences Investment Returns
Long-Term Investment Performance Analysis
Roivant Sciences stock price in Dec 2020 was $9.92, A $1,000.00 lump sum investment in Roivant Sciences made 5 years ago would be worth approximately $3,027.22 today, representing a outstanding return of 202.72%. This translates to an annualized return (CAGR) of 22.22%.
5 Years 6 Months Investment Scenario (Dec 2020 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ROIV's 52-week high and low?
- In the last 52 weeks, Roivant Sciences reached a high of $32.79 (on May 20, 2026) and a low of $10.70 (on July 8, 2025).
- What is the market cap and P/E ratio for ROIV?
- Curious about Roivant Sciences's size and valuation? Its market capitalization stands at 20.14B. When it comes to valuation, the P/E ratio (trailing twelve months) is 1.95, and the forward P/E (looking ahead) is -25.15.
- Does ROIV pay dividends? If so, what's the yield?
- As for dividends, Roivant Sciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Roivant Sciences's main competitors or similar companies to consider before investing?
When looking at Roivant Sciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology -2.31% 27.89% Regeneron
REGN80.98B Healthcare Biotechnology 15.66% -21.83% Alnylam
ALNY41.87B Healthcare Biotechnology -8.16% 40.32% Insmed
INSM31.05B Healthcare Biotechnology -0.89% 389.25% Revolution Medicines
RVMD28.61B Healthcare Biotechnology 279.08% 524.98% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Roivant Sciences Ltd? (e.g., ROE, Debt/Equity)
- To get a sense of Roivant Sciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -19.14%, the Debt to Equity ratio from the most recent quarter is 2.19, and its Gross Profit Margin stands at 64.98%.
- What is the recent revenue and earnings growth for ROIV?
- Looking at Roivant Sciences's growth, its revenue over the trailing twelve months (TTM) was $13M. Compared to the same quarter last year (YoY), quarterly revenue grew by -77.80%, and quarterly earnings saw a YoY growth of -77.83%.
- How much of ROIV stock is held by insiders and institutions?
- Wondering who owns Roivant Sciences stock? Company insiders (like executives and directors) hold about 22.76% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 72.91%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.